Research and Markets: Vaccines Review and Outlook 2010

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/30e9e2/vaccines_review_an) has announced the addition of the "Vaccines Review and Outlook 2010" report to their offering.

The global vaccine market is expected to achieve $34 billion in sales by 2012. With an estimated annual growth rate of 14% during the next five years, vaccines will be the fastest-growing therapeutic area, even outpacing oncology.

The recently renewed interest in the vaccine sector is attributed to advances in technology, federal liability protection for developers, increasing global demand, and premium pricing for new products.

The impact of vaccines on global health and economic development is enormous. Vaccines have saved more lives than any health intervention since global access to clean drinking water. According to the CDC, a dozen deadly diseases targeted by childhood vaccinations have been eliminated or have declined more than 90% during the past century in the United States.

Despite the availability of vaccines, there is massive unmet medical need in the battles against childhood diseases in developing nations, chronic diseases such as diabetes and cancer, and other wide-spread or up-and-coming conditions such as HIV/AIDS, meningitis, and dengue. Even the seasonal influenza segment holds significant opportunities to improve market penetration, shelf stability, and delivery.

One of the most striking vaccine advances in recent years is active immunotherapies, including the April 2010 FDA approval of Dendreon's Provenge, a personalized vaccine targeting prostate cancer. Active immunotherapy stimulates the patient's immune system to fight cancer while sparing the patient most of the adverse side effects associated with chemotherapy, radiation, and other biologics that target antigens. The anti-cancer activity persists long after a course of treatment. These vaccines feature new modes of action and present opportunities for development of combination therapies to provide exceptional long-term tumor control. Therapeutic vaccines are also being researched for the treatment of HIV, hepatitis C, and more.

Key Topics Covered:

  • Vaccine Market Overview
  • Vaccines Licensed for Immunization and Distribution in the U.S.
  • Vaccine Prescription Medicine Pipeline.45
  • Awaiting Approval
  • Phase III
  • Phase II/III
  • Phase II
  • Phase I/II
  • Phase I
  • Preclinical
  • Vaccine Prescription Medicine Developers and Marketers
  • Oncology Marketed Devices
  • Class III
  • Unclassified
  • Vaccine Medical Device Companies

For more information visit http://www.researchandmarkets.com/research/30e9e2/vaccines_review_an



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America

INDUSTRY KEYWORDS:   Health  Infectious Diseases  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.